Figure 1. AZA and DAC differentially affect cell viability in AML cell lines.

Cell viability of AML cell lines, KG-1a, THP-1, OCI-AML3, and HL-60, was assessed after 72 hours of treatment with AZA (•) or DAC (□) (0–50 µM) using the CellTiter-Glo assay. Standard deviation was determined from 2 or 3 independent experiments, including triplicate wells per experiment. AML  =  acute myeloid leukemia; AZA  =  azacitidine; DAC  =  decitabine.